What question did this study set out to answer?

To investigate the relationship between cumulative chemotherapy dose and survival outcomes in children with average risk medulloblastoma.

March 28, 2026

Cumulative dose of chemotherapy and survival outcomes in children with average risk medulloblastoma treated on Children’s Oncology Group study ACNS0331

Key Points

To investigate the relationship between cumulative chemotherapy dose and survival outcomes in children with average risk medulloblastoma.
Analyzed survival outcomes in children treated under the Children’s Oncology Group study ACNS0331
Examined dose reductions of vincristine and cisplatin
Focused on average risk medulloblastoma cases
Moderate dose reductions (≥25%) in vincristine and cisplatin did not significantly impact survival outcomes
Larger dose reductions (>50%) were not evaluated in the study

Abstract

Moderate dose reductions of at least 25% in vincristine and cisplatin do not significantly affect survival in AR medulloblastoma. Effects of larger dose reductions (>50%) or dose reductions in high-risk disease were not studied.

Cumulative dose of chemotherapy and survival outcomes in children with average risk medulloblastoma treated on Children’s Oncology Group study ACNS0331

Key Points

Abstract

Cite This Study